Can We Design a Nogo Receptor-Dependent Cellular Therapy to Target MS?
The current landscape of therapeutics designed to treat multiple sclerosis (MS) and its pathological sequelae is saturated with drugs that modify disease course and limit relapse rates. While these small molecules and biologicals are producing profound benefits to patients with reductions in annuali...
Uloženo v:
| Hlavní autoři: | , , , , |
|---|---|
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
MDPI AG
2018-12-01
|
| Edice: | Cells |
| Témata: | |
| On-line přístup: | https://www.mdpi.com/2073-4409/8/1/1 |
| Tagy: |
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|